FX.co ★ Transgene: Phase II Study With TG4001 Fails To Meet Primary Objective - Quick Facts

Transgene has announced that its Phase II randomized study, which aimed to assess the efficacy of TG4001 combined with avelumab against avelumab alone in patients with recurrent or metastatic HPV16-positive cervical and anogenital tumors, did not achieve its primary endpoint. However, the company observed a positive efficacy trend in the cervical cancer subgroup favoring the TG4001 regimen, which warrants further validation, including analyses by PD-L1 status. The company is currently conducting an in-depth evaluation of the complete study findings to determine the optimal path forward for this program and will provide additional updates once this analysis is finalized.